Semnur Pharmaceuticals

Company snapshot

Semnur Pharmaceuticals, Inc. is a biopharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients. Back pain affects most adults, second most common cause of disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has in

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Semnur Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Semnur Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   Ixabepilone + Capecitabine — Phase 3

2. May 23, 2026 Clinical update

   SP-102 — Phase 3

3. Apr 29, 2025 Patent grant

   Methods of treating pain

4. Jun 25, 2024 Patent grant

   Methods of treating inflammation and/or pain

5. Jun 21, 2022 Patent grant

   Pharmaceutical formulation

View all clinical trial activity →

• What is Semnur Pharmaceuticals?

  Semnur Pharmaceuticals is a pharma organization headquartered in Palo Alto, USA. It trades on NYSE under ticker SMNR. Primary therapeutic focus areas include Breast Cancer, Lumbosacral Radicular Pain. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 8 patent rec

• Is Semnur Pharmaceuticals publicly traded?

  Yes. Semnur Pharmaceuticals is listed with ticker SMNR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Semnur Pharmaceuticals develop or market?

  We link 2 drug profile(s) where Semnur Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/semnur-pharmaceuticals#company-drugs.

• What are the latest developments for Semnur Pharmaceuticals?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Semnur Pharmaceuticals focus on?

  Semnur Pharmaceuticals focuses on Breast Cancer, Lumbosacral Radicular Pain based on our analysis of their pipeline programs and drug development activities.